Dexrazoxane vs no cardioprotective intervention
Cardiomyopathy/heart failure primary cause of death Available‐case analysis · children with cancer receiving anthracyclines
1 finding from 1 review
- Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 1008 participantsLow